Enveric raises $2.2M in warrant exercise inducement; issues new Series C/D warrants

Enveric Biosciences, Inc.

Holders exercised 1,212,499 Series A and 1,212,499 Series B warrants at reduced price of $0.915/share.
Gross proceeds ~$2.2M; H.C. Wainwright acted as placement agent (7% fee).
Company issued new unregistered Series C (2,424,998 shares, 5-yr term) and Series D (2,424,998 shares, 18-mo term) warrants at $0.915.
New warrants exercisable only after stockholder approval; proceeds for working capital and product development.

Key facts

Extracted from this filing and checked against the source text.

Equity Issuances SEC 8-K Item 3.02/3.03 confidence 0.9

Enveric Biosciences, Inc. issued up to 2,424,998 shares of Common Stock of warrant to certain institutional investors (the "Holders") for aggregate gross proceeds of approximately $2.2 million from the exercise of the Existing Warrants by the Holders, before deducing placement agent fees.

Security: warrant
Shares: up to 2,424,998 shares of Common Stock
Purchaser: certain institutional investors (the "Holders")
Consideration: aggregate gross proceeds of approximately $2.2 million from the exercise of the Existing Warrants by the Holders, before deducing placement agent fees

Exact text from the filing

(the “New Series D Warrant Shares” and, together with the New Series C Warrant Shares, the “New Warrant Shares.”) The Company received aggregate gross proceeds of approximately $2.2 million from the exercise of the Existing Warrants by the Holders, before deducing placement agent fees and other offering expenses payable by the Company. The Company engaged H.C.

View on SEC.gov

Browse all equity issuances →

Enveric Biosciences, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-25-014073

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.